메뉴 건너뛰기




Volumn 2, Issue 4, 2000, Pages 448-452

Technology evaluation: Gene therapy (IL-2), Valentis Inc

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHOLESTEROL; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2; LIPOFECTIN; LIPOSOME;

EID: 0033838978     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (13)

References (25)
  • 2
    • 0008262203 scopus 로고    scopus 로고
    • GeneMedicine Inc: GeneMedicine commences IL-2 cancer GeneMedicine phase I clinical trial. Press release 21 August
    • (1997)
  • 3
    • 0008224023 scopus 로고    scopus 로고
    • GeneMedicine Inc: GeneMedicine receives $5.25 million from Corange under cancer alliance. Press release 10 February
    • (1998)
  • 7
    • 0008261474 scopus 로고    scopus 로고
    • GeneMedicine Inc: GeneMedicine initiates phase I/II clinical trials using interferon-α gene therapy. Press release 16 March
    • (1999)
  • 9
    • 0008184905 scopus 로고    scopus 로고
    • Valentis Inc: Valentis Inc initiates phase II clinical trial with interleukin-2 gene medicine. Press release 29 June
    • (1999)
  • 11
    • 0008190138 scopus 로고    scopus 로고
    • Valentis Inc: Valentis Inc initiates phase I/II clinical trial with interleukin-12 gene therapy. Press release 21 July
    • (1999)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.